A subsidiary resolved to commence a clinical trial of an ADRC-based therapy derived from adipose tissue targeting severe limb ischemia. Consultation on the clinical trial protocol with the PMDA has been completed, and the joint research agreement with Nagoya University will continue. The company aims for practical application and insurance coverage in the future, but the impact on financial results is currently undetermined and under review.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"3750","jir_company_name":"ADR Biomedical Holdings Inc.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-10-28","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/3750-20261028-01.pdf","jir_short_summary":"A subsidiary resolved to commence a clinical trial of an ADRC-based therapy derived from adipose tissue targeting severe limb ischemia. Consultation on the clinical trial protocol with the PMDA has been completed, and the joint research agreement with Nagoya University will continue. The company aims for practical application and insurance coverage in the future, but the impact on financial results is currently undetermined and under review.","jir_summary":"### Overview of Clinical Trial Initiation and Research Framework\nThe subsidiary ADR Therapeutics Inc. resolved at its board meeting to commence a clinical trial of a therapy using adipose-derived regenerative cells (ADRCs) targeting severe limb ischemia. It emphasizes verification under the joint research agreement with Nagoya University and that consultation with the PMDA on the clinical trial protocol has been completed.\n\n### Future Impact on Financial Results and Schedule\nThe direct impact of commencing the clinical trial on financial results is currently under review, and any matters requiring disclosure will be announced promptly. The clinical trial is at a verification stage aimed at practical application and insurance coverage, and no specific figures have been disclosed at this time.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#ADRBiomedicalHoldings, #ClinicalTrialStart, #BusinessStrategy","jir_key_figures":"Resolution to commence clinical trial (date TBD)\nJoint research agreement: Concluded with Nagoya University (previously reported)\nPMDA clinical trial protocol consultation completed (previously reported)","jir_meta_title":"ADR Biomedical Holdings Inc. Announces Start of Clinical Trial for Severe Limb Ischemia | October 2026","jir_meta_description":"ADR Biomedical Holdings Inc. announces that its subsidiary has started a clinical trial of a therapy. The program follows joint research with Nagoya University and PMDA consultations as it pursues practical application and insurance coverage. Financial impact is currently unknown.","jir_og_title":"ADR Biomedical Holdings Inc. Announces Start of Clinical Trial for Severe Limb Ischemia","jir_og_description":"The subsidiary resolved to begin a clinical trial of an ADRC-based therapy targeting CLI. PMDA consultation completed and joint research continues, aiming for practical application and insurance coverage.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59367,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-135496","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n